戻る Agenda
Companion Diagnostics: Could Co-Development be Expedited to Facilitate Access to Accelerated Novel Therapeutics?
Session Chair(s)
Megan Doyle, JD, MPH
Associate Vice President, Assistant General Counsel - Diagnostics
Eli Lilly & Company, United States
Novel targeted therapies can reach patients faster than ever before. Many require development of a companion diagnostic. Novel solutions for expedited co-development and review practices is needed for CDx that are paired with accelerated therapeutics.
Learning Objective : Discuss methods to accelerate CDx co-development to enable earlier patient access to novel, innovative therapies; Describe current challenges in companion diagnostic co-development for accelerated therapies; Identify possible approaches to address this problem.
Speaker(s)
Panelist
Jeff Allen, PhD
Friends of Cancer Research, United States
President and Chief Executive Officer
Panelist
Alberto Gutierrez, PhD
NDA Partners, United States
Partner
Panelist
Wendy Rubinstein, MD, PhD, FACP
FDA, United States
Director, Personalized Medicine, OIR, CDRH